News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2024-03-19 6:57:59 pm COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023 InvestorPlace
2024-03-19 5:15:0 am Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results Business Wire
2024-03-12 6:0:0 am Coya Therapeutics to Participate in BTIG Fireside Discussion Business Wire
2024-03-12 5:0:0 am Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference Business Wire
2024-03-06 5:15:0 am Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference Business Wire
2024-02-29 5:15:0 am Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference Business Wire
2024-02-22 5:15:0 am Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference Business Wire
2024-02-21 5:15:0 am Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product" Business Wire
2024-02-13 5:15:0 am Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases Business Wire
   

Please consider a small donation if you think this website provides you with relevant information